DAA’s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?
Sustained Virologic Response Improves Overall Survival in Chronic HCV with Advanced Fibrosis
Interferon has a Dual Mechanism of Action: Viral Inhibition and Immune Modulation
Pharmacokinetics of Once Daily Compared with Twice Daily Regimen of Ribavirin
SPRINT-2 and RESPOND-2: HCV G1 Subtype as a Predictor of SVR in Patients with Poor IFN Response (BOC Arms Combined)
Patients With Poor Interferon Response and Fail Treatment Are More Likely to Have RAVs
REALIZE: Insulin resistance was not an independent determinant of SVR